The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET
Corresponding Author
William E. Klunk
Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA
Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA
Corresponding author. Tel.: +1-412-246-6460; Fax: +1-412-246-6465. [email protected]Search for more papers by this authorRobert A. Koeppe
Department of Radiology, University of Michigan, Ann Arbor, MI, USA
Search for more papers by this authorJulie C. Price
Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA
Search for more papers by this authorTammie L. Benzinger
Department of Radiology, Massachusetts General Hospital, Boston, MA, USA
Department of Neurosurgery, Washington University, Saint Louis, MO, USA
Search for more papers by this authorMichael D. Devous Sr.
Department of Neurology, UT Southwestern Medical Center, Dallas, TX, USA
Department of Radiology, UT Southwestern Medical Center, Dallas, TX, USA
Search for more papers by this authorWilliam J. Jagust
Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, CA, USA
Search for more papers by this authorKeith A. Johnson
Department of Radiology, Massachusetts General Hospital, Boston, MA, USA
Department of Neurology, Massachusetts General Hospital, Boston, MA, USA
Search for more papers by this authorChester A. Mathis
Departments of Radiology, Pharmacology and Biological Chemistry, and Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA, USA
Search for more papers by this authorDavneet Minhas
Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA
Search for more papers by this authorMichael J. Pontecorvo
Avid Radiopharmaceuticals, Philadelphia, PA, USA
Search for more papers by this authorChristopher C. Rowe
Department of Nuclear Medicine and Centre for PET, Austin Health, Melbourne, VIC, Australia
Search for more papers by this authorDaniel M. Skovronsky
Avid Radiopharmaceuticals, Philadelphia, PA, USA
Search for more papers by this authorMark A. Mintun
Avid Radiopharmaceuticals, Philadelphia, PA, USA
Search for more papers by this authorCorresponding Author
William E. Klunk
Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA
Department of Neurology, University of Pittsburgh, Pittsburgh, PA, USA
Corresponding author. Tel.: +1-412-246-6460; Fax: +1-412-246-6465. [email protected]Search for more papers by this authorRobert A. Koeppe
Department of Radiology, University of Michigan, Ann Arbor, MI, USA
Search for more papers by this authorJulie C. Price
Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA
Search for more papers by this authorTammie L. Benzinger
Department of Radiology, Massachusetts General Hospital, Boston, MA, USA
Department of Neurosurgery, Washington University, Saint Louis, MO, USA
Search for more papers by this authorMichael D. Devous Sr.
Department of Neurology, UT Southwestern Medical Center, Dallas, TX, USA
Department of Radiology, UT Southwestern Medical Center, Dallas, TX, USA
Search for more papers by this authorWilliam J. Jagust
Helen Wills Neuroscience Institute, University of California Berkeley, Berkeley, CA, USA
Search for more papers by this authorKeith A. Johnson
Department of Radiology, Massachusetts General Hospital, Boston, MA, USA
Department of Neurology, Massachusetts General Hospital, Boston, MA, USA
Search for more papers by this authorChester A. Mathis
Departments of Radiology, Pharmacology and Biological Chemistry, and Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA, USA
Search for more papers by this authorDavneet Minhas
Department of Radiology, University of Pittsburgh, Pittsburgh, PA, USA
Search for more papers by this authorMichael J. Pontecorvo
Avid Radiopharmaceuticals, Philadelphia, PA, USA
Search for more papers by this authorChristopher C. Rowe
Department of Nuclear Medicine and Centre for PET, Austin Health, Melbourne, VIC, Australia
Search for more papers by this authorDaniel M. Skovronsky
Avid Radiopharmaceuticals, Philadelphia, PA, USA
Search for more papers by this authorMark A. Mintun
Avid Radiopharmaceuticals, Philadelphia, PA, USA
Search for more papers by this authorAbstract
Although amyloid imaging with PiB-PET ([C-11]Pittsburgh Compound-B positron emission tomography), and now with F-18-labeled tracers, has produced remarkably consistent qualitative findings across a large number of centers, there has been considerable variability in the exact numbers reported as quantitative outcome measures of tracer retention. In some cases this is as trivial as the choice of units, in some cases it is scanner dependent, and of course, different tracers yield different numbers. Our working group was formed to standardize quantitative amyloid imaging measures by scaling the outcome of each particular analysis method or tracer to a 0 to 100 scale, anchored by young controls (≤45 years) and typical Alzheimer's disease patients. The units of this scale have been named “Centiloids.” Basically, we describe a “standard” method of analyzing PiB PET data and then a method for scaling any “nonstandard” method of PiB PET analysis (or any other tracer) to the Centiloid scale.
Supporting Information
| Filename | Description |
|---|---|
| alzjjalz201407003-sup-0001.jpgapplication/jpg, 1.4 MB | Supplemental Flowchart 1 |
| alzjjalz201407003-sup-0002.jpgapplication/jpg, 1.1 MB | Supplemental Flowchart 2 |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
References
- [1]GB Frisoni, CR Jack. Harmonization of magnetic resonance-based manual hippocampal segmentation: a mandatory step for wide clinical use. Alzheimers Dement. 7: 2011; 171–174
- [2]CR JackJr., F Barkhof, MA Bernstein, M Cantillon, PE Cole, C Decarli, et al. Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. Alzheimers Dement. 7: 2011; 474–485.e4
- [3]M Boccardi, M Bocchetta, R Ganzola, N Robitaille, A Redolfi, S Duchesne, et al. Operationalizing protocol differences for EADC-ADNI manual hippocampal segmentation. Alzheimers Dement201310.1016/j.jalz.2013.03.001(in press)
- [4]GB Frisoni, M Bocchetta, G Chetelat, GD Rabinovici, MJ de Leon, J Kaye, et al. Imaging markers for Alzheimer disease: which vs how. Neurology. 81: 2013; 487–500
- [5]H Vanderstichele, M Bibl, S Engelborghs, N Le Bastard, P Lewczuk, JL Molinuevo, et al. Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's biomarkers standardization initiative. Alzheimers Dement. 8: 2012; 65–73
- [6]MC Carrillo, K Blennow, H Soares, P Lewczuk, N Mattsson, P Oberoi, et al. Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: an update from the Alzheimer's Association Global Biomarkers Consortium. Alzheimers Dement. 9: 2013; 137–140
- [7]MA Mintun, GN Larossa, YI Sheline, CS Dence, SY Lee, RH Mach, et al. [11, C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology. 67: 2006; 446–452
- [8]JC Morris, PS Aisen, RJ Bateman, TL Benzinger, NJ Cairns, AM Fagan, et al. Developing an international network for Alzheimer research: The Dominantly Inherited Alzheimer Network. Clin Investig (Lond). 2: 2012; 975–984
- [9]H Oh, C Madison, TJ Haight, C Markley, WJ Jagust. Effects of age and beta-amyloid on cognitive changes in normal elderly people. Neurobiol Aging. 33: 2012; 2746–2755
10.1016/j.neurobiolaging.2012.02.008 Google Scholar
- [10]CC Rowe, KA Ellis, M Rimajova, P Bourgeat, KE Pike, G Jones, et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging. 31: 2010; 1275–1283
- [11]JC Morris, CM Roe, C Xiong, AM Fagan, AM Goate, DM Holtzman, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 67: 2010; 122–131
- [12]G McKhann, D Drachman, M Folstein, R Katzman, D Price, EM Stadlan. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 34: 1984; 939–944
- [13]HJ Aizenstein, RD Nebes, JA Saxton, JC Price, CA Mathis, ND Tsopelas, et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol. 65: 2008; 1509–1517
- [14]CC Rowe, S Ng, U Ackermann, SJ Gong, K Pike, G Savage, et al. Imaging beta-amyloid burden in aging and dementia. Neurology. 68: 2007; 1718–1725
- [15]GD Rabinovici, AJ Furst, JP O'Neil, CA Racine, EC Mormino, SL Baker, et al. 11, C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology. 68: 2007; 1205–1212
- [16]JC Morris. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 43: 1993; 2412–2414
- [17]NC Schwertman, R de Silva. Identifying outliers with sequential fences. Computational Statistics & Data Analysis. 51: 2007; 3800–3810
- [18]AD Cohen, W Mowrey, LA Weissfeld, HJ Aizenstein, E McDade, JM Mountz, et al. Classification of amyloid-positivity in controls: comparison of visual read and quantitative approaches. Neuroimage. 71: 2013; 207–215
- [19]AD Cohen, JC Price, LA Weissfeld, J James, BL Rosario, W Bi, et al. Basal cerebral metabolism may modulate the cognitive effects of Aβ in mild cognitive impairment: an example of brain reserve. J Neurosci. 29: 2009; 14770–14778
- [20]JC Price, WE Klunk, BJ Lopresti, X Lu, JA Hoge, SK Ziolko, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab. 25: 2005; 1528–1547
- [21]J Ashburner, KJ Friston. Nonlinear spatial normalization using basis functions. Hum Brain Mapp. 7: 1999; 254–266
- [22]J Ashburner. A fast diffeomorphic image registration algorithm. Neuroimage. 38: 2007; 95–113
- [23]J Ashburner, KJ Friston. Unified segmentation. Neuroimage. 26: 2005; 839–851
- [24]WE Klunk, H Engler, A Nordberg, Y Wang, G Blomqvist, DP Holt, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol. 55: 2004; 306–319
- [25]J Mazziotta, A Toga, A Evans, P Fox, J Lancaster, K Zilles, et al. A probabilistic atlas and reference system for the human brain: International Consortium for Brain Mapping (ICBM). Philos Trans R Soc Lond B Biol Sci. 356: 2001; 1293–1322
- [26]N Tolboom, M Yaqub, R Boellaard, G Luurtsema, AD Windhorst, P Scheltens, et al. Test-retest variability of quantitative [11C]PIB studies in Alzheimer's disease. Eur J Nucl Med Mol Imaging. 36: 2009; 1629–1638
- [27]M Yaqub, N Tolboom, R Boellaard, BN van Berckel, EW van Tilburg, G Luurtsema, et al. Simplified parametric methods for [11C]PIB studies. Neuroimage. 42: 2008; 76–86
- [28]DT Chien, S Bahri, AK Szardenings, JC Walsh, F Mu, MY Su, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis. 34: 2013; 457–468
- [29]M Maruyama, H Shimada, T Suhara, H Shinotoh, B Ji, J Maeda, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron. 79: 2013; 1094–1108
- [30]N Okamura, S Furumoto, R Harada, T Tago, T Yoshikawa, M Fodero-Tavoletti, et al. Novel 18F-labeled arylquinoline derivatives for noninvasive imaging of tau pathology in Alzheimer disease. J Nucl Med. 54: 2013; 1420–1427
- [31]K Herholz, E Salmon, D Perani, JC Baron, V Holthoff, L Frolich, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage. 17: 2002; 302–316
- [32]T Yamane, Y Ikari, T Nishio, K Ishii, T Kato, K Ito, et al. Visual-statistical interpretation of 18F-FDG-PET images for characteristic Alzheimer patterns in a multicenter study: inter-rater concordance and relationship to automated quantitative evaluation. AJNR Am J Neuroradiol. 35: 2014; 244–249
- [33]WJ Jagust, D Bandy, K Chen, NL Foster, SM Landau, CA Mathis, et al. The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement. 6: 2010; 221–229
- [34]WE Klunk, JC Price, CA Mathis, ND Tsopelas, BJ Lopresti, SK Ziolko, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci. 27: 2007; 6174–6184
- [35]VL Villemagne, S Ataka, T Mizuno, WS Brooks, Y Wada, M Kondo, et al. High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. Arch Neurol. 66: 2009; 1537–1544
- [36]AD Cohen, W Bi, LA Weissfeld, HA Aizenstein, E McDade, JM Mountz, et al. Classification of amyloid-positivity in controls: comparison of visual read and quantitative approaches. Neuroimage. 71: 2012; 207–215
- [37]EC Mormino, MG Brandel, CM Madison, GD Rabinovici, S Marks, SL Baker, et al. Not quite PIB-positive, not quite PIB-negative: slight PIB elevations in elderly normal control subjects are biologically relevant. Neuroimage. 59: 2012; 1152–1160
- [38]W Klunk, A Cohen, W Bi, L Weissfeld, H Aizenstein, E McDade, et al. Why we need two cutoffs for amyloid imaging: early versus Alzheimer's-like amyloid-positivity. Alzheimers Dement. 8: 2012; P453–P454
10.1016/j.jalz.2012.05.1208 Google Scholar
- [1]J Ashburner, KJ Friston. Nonlinear spatial normalization using basis functions. Hum Brain Mapp. 7: 1999; 254–266
Citing Literature
